



HHS Public Access

Author manuscript

Dermatol Ther. Author manuscript; available in PMC 2023 November 01.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Published in final edited form as:

Dermatol Ther. 2022 November ; 35(11): e15842. doi:10.1111/dth.15842.

Complementary and alternative therapies in skin cancer: A literature review of biologically active compounds.

Leonel Hidalgo, MD¹, Cristóbal Saldías-Fuentes, MD², Karina Carrasco, RDN^{1,3}, Allan C. Halpern, MD⁴, Jun J. Mao, MD⁵, Cristian Navarrete-Decent, MD.^{1,6}

¹Department of Dermatology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

²Dermatology Service, Hospital Dr. Carlos Cisternas de Calama, Calama, Chile

³Hospital Nutrition Unit, Fundación Arturo López Pérez, Santiago, Chile.

⁴Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

⁵Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

⁶Melanoma and Skin Cancer Unit, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Abstract

Introduction: Complementary and alternative medicine or therapies (CAM) are frequently used by skin cancers patients. Patient's self-administration of CAM in melanoma can reach up to 40–50%. CAMs such as botanical agents, phytochemicals, herbal formulas ("black salve") and cannabinoids, among others, have been described in skin cancer patients.

Objective: To acknowledge the different CAM for skin cancers through the current evidence, focusing on biologically active CAM rather than mind-body approaches.

Methods: We searched MEDLINE database for articles published through July 2022, regardless of study design.

Results: Of all CAMs, phytochemicals have the best in vitro evidence supporting efficacy against skin cancer including melanoma; however, to date, none have proved efficacy on human patients. Of the phytochemicals, Curcumin is the most widely studied. Several findings support

Corresponding author: Cristian Navarrete-Decent, MD, Department of Dermatology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Diagonal Paraguay 362, 6th floor, Santiago, Chile 8330077, Phone: +56-2-2435 3574, ctnavarra@gmail.com.

Authorship Contributions:

- (1) Acquisition, analysis, and interpretation of data.
- (2) Drafting and revising the article.
- (3) Final approval of the version to be published.

Conflict of interest: The authors have not conflict of interest to declare.

Consent for publication: The authors consent the publication of this submission (manuscript and figures).

Prior presentation: none.

IRB status: N/A.

Curcumin efficacy in vitro through various molecular pathways, although most studies are in the preliminary phase. In addition, the use of alternative therapies is not exempt of risks: physicians should be aware of their adverse effects, interactions with standard treatments, and possible complications arising from CAM usage.

Conclusion: There is emerging evidence for CAM use in skin cancer, but no human clinical trials support the effectiveness of any CAM in the treatment of skin cancer to date. Nevertheless, patients worldwide frequently use CAM, and physicians should educate themselves on currently available CAMs.

Keywords

skin cancer; melanoma; non-melanoma skin cancer; complementary therapy; complementary and alternative medicine

Introduction:

Skin cancer is the most frequent malignancy in humans. Both melanoma and non-melanoma skin cancer (NMSC) have a growing incidence and relatively stable mortality. Dermatology patients are referring a growing interest in complementary and alternative medicine (CAM) therapies.¹ The National Institute of Health (NIH): National Center for Complementary and Integrative Health defines CAM as “a group of diverse medical and health care practices and products that are not presently considered to be part of conventional medicine”.¹ The use of CAM is a growing phenomenon, and even some (like ‘Kampo medicines’) are covered by health insurances. A survey of 400 directors of private clinics of Japan reported that dermatology was the third medical specialty that prescribed ‘Kampo medicines’ more frequently.² Dietary supplements (other than vitamins and minerals) are the most commonly used CAM, followed by mind-body approaches (e.g., deep-breathing exercises and acupuncture, among others).^{1,3} It has been reported that up to 85% of dermatology patients use CAM at some point, more commonly older women.¹ CAM data use in skin cancer patients is scarce with most information coming from melanoma patients. It has been reported that ~20% of NMSC patients⁴ and 40–50% of melanoma patients have used CAM at some point, especially on those with advanced disease.⁵

Trust in conventional medicine and compliance to physician’s suggestions showed no difference between CAM users and non-users; however, the feeling of less emotional support from the medical team was significantly higher in the conventional medicine group.⁵ In a study, the largest source of information reported by CAM users was print media, family and friends, physicians, and the internet.³ However, there are reliable resources for finding information regarding complementary health approaches that could be useful to clinicians (Table 1). Herein we performed a literature review on different CAMs for skin cancer. We focused solely on biologically active CAM rather than mind-body approaches. Our objective was to create a resource for dermatologists on different CAMs reported on skin cancer patients.

Methods:

We searched MEDLINE database for articles published through July 2022, using the keywords: (“melanoma” or “nonmelanoma” or “non-melanoma” or “basal cell carcinoma” or “squamous cell carcinoma”) AND (“cutaneous” or “skin” or “skin cancer” AND “complementary therapy” or “complementary medicine” or “alternative therapy” or “alternative medicine” or “non-traditional medicine” or “non-classical medicine”). References within retrieved articles were also reviewed to identify potentially missed studies. We included all studies published to date, in English and/or Spanish, regardless of study design. Exclusion criteria were languages other than English or Spanish and unavailability of the full article. Duplicates were reviewed and excluded.

Results:

I. Complementary and alternative therapies in non-melanoma skin cancer:

Despite 18% of patients with NMSC reported any CAM use, only 1% used it as a primary treatment (alternative use).⁴ Herein we discuss those with reported outcomes or clinical relevance. No studies on CAM use on systemic/metastatic NMSC were found. Table 2 summarizes the findings.

1. Botanical agents (herbs): Botanical agents or “herbs” is used to refer to the whole plant without extraction of the active substances. The active substances of botanical agents are named “Phytochemicals”. The biologic effect of a botanical agent mainly comes from its “phytochemicals”, but it is not limited to it as other components might have relevant effects. Botanical agents have some biological activity in NSMC, mostly in murine models. Botanical agents with proven biological effect on skin tumors include: Goldenseal (*Hydrastis canadensis*),⁶ pond apple (*Annona glabra*),⁷ bitter melon (*Momordica charantia*),⁸ ginger (*Zingiber officinale*),⁶ frankincense (*Boswellia serrata*),⁹ and willow-tree bark (*Salix caprea*).⁶ The glycoalkaloids from Sodom apple plant (*Solanum sodomaeum*) have shown efficacy on basal cell carcinoma (BCC), squamous cell carcinoma (SCC), keratoacanthomas, and actinic keratoses when used topically (cream) in humans.⁶ Plants of the genus *Gelsemium* showed growth reduction of topical carcinogens induced papilloma and skin cancer in mice.¹⁰ *Polypodium leucotomos* has been shown to increase the efficacy of photodynamic therapy in the treatment of actinic keratosis in humans.¹¹ Some botanical agents showed photoprotective effects against ultraviolet radiation (UVR), such as red clover flowers (*Trifolium pretense*),⁶ flower of Orpheus (*Haberlea rhodopensis*), grape seed extract,¹² green tea,¹² golden polypody (*Polypodium leucotomos*),¹¹ and ground pine (*Lycopodium clavatum*).¹³

1.1 Phytochemicals: Phytochemicals can modulate multiple biochemical pathways involved in carcinogenesis and can protect cells from damage from free radicals and ultraviolet radiation (UVR). The most relevant type of phytochemicals with anticancer activity are polyphenols, particularly flavonoids, mainly from parsley and celery.

Those with activity in skin tumors and NMSC are resveratrol,¹⁴ cryptolepine, apigenin,¹³ and curcumin (Diferuloylmethane).¹⁵ Curcumin was particularly evaluated for SCC. A

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

phase I trial in humans demonstrated that 8000 mg/day curcumin were non-toxic when taken orally for 3 months, and suggested biologic effect in premalignant lesions, including arsenical Bowen's disease and oral leukoplakia.¹⁶ Phytochemicals with photoprotective activity include silibinin¹² and curcumin.

Curcuminoids: Curcuminoids are a spice with a yellow color extracted from the roots of the *Curcuma longa* herb (Turmeric), which belongs to the ginger family. Curcumin is also known as 'Golden spice' because of its yellow color found in curry powder.¹⁵ Curcuminoids consist of diferuloylmethane (curcumin), desmethoxycurcumin, and bisdemethoxycurcumin.¹⁵ A study in human oral squamous cell carcinoma (HNO97 cell line) showed inhibition in proliferation, morphological changes (apoptosis-like), alterations in cell cycle distribution, and DNA damage.¹⁵ Also investigators found apoptosis induction and suppression of colony-forming ability in a time-dependent manner.¹⁵

Silymarin/Silibinin: Silymarin is isolated from the seed of milk thistle (*Silybum marianum*, Asteraceae family), which is an annual or biennial Mediterranean native herb.¹² Silibinin is a constituent of silymarin. Investigators found protective effect of silibinin against UVB induced-photocarcinogenesis. Silibinin accelerated the removal of UVB-induced DNA damage products and reduction of tumor number, multiplicity, and volume in p53+/+ mice.¹² They also reported a silibinin effect against UVB-induced genomic instability; inhibitory effect against skin SCC/BCC growth and proliferation; induction of apoptotic cell death of skin epidermal cells after UVB exposure; inhibitory effect on molecular expression and activation of inflammatory molecules and oxidative pathways (essential in tumorigenesis); and a inhibitory effect against drug-resistant BCC cells (via targetin EGFR/AKT and Hedghog pathway).¹²

Cannabinoids: Cannabinoid receptors are expressed in both NMSC and melanoma.¹⁷ Studies have shown *in vivo* and *in vitro* effects on NMSC.¹⁷ In mice, local administration of cannabinoids prevented growth and vascularization of malignant epidermal tumor cells.¹⁷ Anandamide, an endocannabinoid, may be elevated in skin tumor cells, leading to endocannabinoid-induced apoptosis and tumor cells death.¹⁷ No study has been performed in humans, yet. Furthermore, cannabinoids may have immunosuppressive potential and tumor promoting effects.¹⁸

2. Herbal formulas:

Most of the preparations found on the internet are herbal 'formulas' of mixed compounds, including zinc chloride, urea, apricot pits, bloodroot and goldenseal.⁶ Of these, escharotic agents are the most notorious, with corrosive properties that produce eschars and scarring. The most frequently used escharotic agent is "black salve".¹⁹

2.1 "Black salve": "Black salve" paste has been widely promoted for its supposed ability to eradicate BCC through topical application on social media and online forums.¹⁹ The composition of "black salve" varies, but it usually includes zinc chloride, and powdered bloodroot from *Sanguinaria canadensis*. Bloodroot probably inhibits nuclear factor-kappa B (NF- κ B), inducing selective apoptosis of cancer cells in *in vitro*.¹⁹ Histopathological

analysis showed scarring, granulomatous responses, extensive necrosis, and suppurative inflammation.²⁰ “Black salve” treatment efficacy for BCC varies, from complete remission with no residual tumor on biopsy to residual infiltrating BCC.²⁰ The latter is found more frequently, and moreover, the resulting ulcer from escharotics can last up to 6 months.²⁰ As escharotics appear to work on the base of direct tissue destruction, the efficacy of “black salve” depends on the extent of the tumor relative to the amount applied.

II. Complementary and alternative therapies in melanoma:

The most frequent CAM reported among melanoma patients are dietary supplements.³ Reported satisfaction is less than 50% in melanoma patients; mind-body alternatives have shown higher satisfaction rates.³ Interestingly, some research has evaluated its potential role on systemic/metastatic disease. Table 3 summarizes the findings.

1. Botanical agents (herbs): Melanoma models have shown anticancer effect of multiple botanical agents through diverse molecular pathways: Tea tree oil (*Melaleuca alternifolia*),⁶ slippery elm (*Ulmus pumila*), chaparral (*Larrea tridentata*),²¹ *Alpinia galanga*,²² flower buds of Henna (*Lawsonia inermis*),²³ young green barley (*Hordeum vulgare L.*),²⁴ the desert plant *Anastatica hierochuntica*,²⁵ homeopathic mother tincture (*Phytolacca decandra*),²⁶ gurmar or woody climber tree (*Gymnema sylvestre*),²⁷ *Hibiscus rosa-sinensis* flower extract,²⁸ Lingzhi (*Ganoderma lucidum*),²⁹ and yellow jessamine (*Gelsemium sempervirens*).¹⁰ *Ferula* species mixed with derivatives of curcumin showed no cytotoxic effect on SK-MEL-28 melanoma cells.³⁰ Finally, the water extracts of *Solanum nigrum*, a herb in traditional Chinese medicine, has cytotoxic effect against human melanoma cell lines and inhibited the metastasis of mouse melanoma cells.³¹

1.1 Phytochemicals: Phytochemicals with proven *in vitro* activity in melanoma models are: Capsaicin, found in chili peppers;³² genistein, found in soybeans;³³ indole-3-carbinol, found in vegetables including broccoli, cauliflower, and brussels sprouts;³⁴ proanthocyanidins, found in cocoa, grapes, apple, tea and red wine;³⁵ resveratrol, found in grapes, peanuts, mulberries, cranberries, and eucalyptus;¹⁴ fisetin, found in strawberries; mangoes, kiwis, apples, grapes, persimmons, cucumbers and onions;³⁶ luteolin found in carrots, peppers, celery, olives, peppermint, thyme, rosemary, and oregano;³⁷ apigenin, found in as parsley, celery, artichokes and chamomile;¹³ betulinic acid, found in the birch bark;³⁸ quercetin, found in apples, berries, and onions; Berberine, found in roots of plants from the genus *Berberis*;³⁹ Pancratistatin, obtained from the beach spider lily (*Hymenocallis littoralis*);³⁹ Paradise tree extract, isolated from the Lakshmi Taru (*Simarouba glauca*);³⁹ and silymarin (*Silybum marianum*).¹² Some of the propolis compounds have shown biological activity, such as chrysin, which has been shown to stimulate IL-2 and IL-10 expression in murine melanoma cells, and galangin, which downregulates ERK 1/2 and activates p38 MAP kinases in human melanoma cells. Chitosan nanoparticles containing limonene and limonene-rich essential oils (*Citrus sinensis* and *Citrus limon*) showed viability reduction on melanoma cell line A375, but the mechanism is unknown.⁴⁰

Of note, some phytochemicals have shown potential benefit on metastatic disease. For instance, catechins (present in green tea extract) have been shown to modulate cancer

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

cell growth, metastasis, angiogenesis, and other aspects of cancer progression by affecting different mechanisms.⁴¹ Epidemiological studies suggest that regular consumption of green tea and ginseng attenuates the risk of many cancers. The main catechin with anticancer activity in green tea is epigallocatechin-3-gallate, with evidence showing promising effects in melanoma models.⁴¹

Curcumin: Curcumin anti-neoplastic and anti-angiogenic effects have been reported widely. Multiple studies have used curcumin or its analogues,⁴² because of its known potent anti-angiogenic, antiproliferative and proapoptotic effects in melanoma cells.⁴³ In contrast to NMSC, no human studies on melanoma patients have been reported to date.

How curcumin exerts its antitumoral effects in cutaneous melanoma is yet to be completely elucidated, but it involves anti-inflammatory and anti-oxidative pathways which allow it to selectively target melanoma cells.³⁹ It has been described to interact with NF- κ B,⁴⁴ caspases, miRNA, Bcl-2 protein expression,⁴⁴ inducible nitric oxide synthase inhibition,⁴⁵ downregulation of DNA-dependent protein kinase catalytic subunit; and upregulation of p53, p21, p27, checkpoint kinase 2.⁴⁵ Also by activation of mammalian sterile 20-like kinase 1, downregulation of phosphatase of regenerating liver-3 expression, lowering levels of STAT3 and JAK-2 protein phosphorylation,⁴⁴ pore opening of mitochondrial permeability transition with activation of cell death pathway, inhibition of matrixmetalloproteinase-2 activity, and downregulation of AKT/mTOR, among other effects.⁴³ Non-selective inhibition of cyclic nucleotide phosphodiesterase 1–5 has also been described.⁴³ Curcuminoids have also shown anti-cancer activity, such as EF24, which inhibits the NF- κ B; DM-1, modulating iNOS and COX-2 gene expression; and D6, inducing overexpression of heat shock proteins, among others.⁴²

Because of the limited oral bioavailability of curcumin, different mechanisms have been tested to improve delivery: micelles; transdermal presentations; chitosan-coated nanoparticles; among others. When cooked, curcumin decomposition products include deketene curcumin, with proven toxicity on melanoma cells. Visible light and combined red and blue light irradiation could synergize with curcumin enhancing apoptosis in human melanoma cells.⁴² However, stimulation of natural killer cells with curcumin reduced the level of IL-12- induced IFN- γ secretion and production of granzyme-B or IFN- γ .⁴² These latter immunologic effects imply that curcumin might also adversely affect the responsiveness of immune effector cells to clinically relevant cytokines that possess anti-tumor properties. When evaluating effects on metastatic disease, oral administration of curcumin alone or through chitosan-coated nanoparticles in melanoma-tumor-bearing mice, inhibits the lung metastasis of melanoma by as much as 80%, increasing survival by 144%.⁴²

Berberine: Berberine is a natural isoquinolone alkaloid which can be extracted through the roots of plants from the genus *Berberis*.³⁹ It increases melanoma cell levels of reactive oxygen species (ROS) which causes AMP-activated protein kinase (AMPK) activation, altering the activity of several signaling pathways.³⁹ Signaling molecules such as ERK and p38 MAPK are downregulated preventing invasive effects on cancer cells. A reduction in COX-2, PGE2 and PGE2 receptors prevents cancer cell migration, decreasing metastatic

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

potential for melanoma cells.³⁹ Berberine has been tested on the B16F10 melanoma cell lines through in vitro and in vivo tests in combination with doxorubicin. Berberine and doxorubicin combination caused tumor volume (85%) decrease and weight (78%) loss when compared to control mice.³⁹

Pancratistatin: Pancratistatin is obtained from the beach spider lily (*Hemanocallis littoralis*). It is thought that targets mitochondrial vulnerabilities which are unique to cancer cells. It induces apoptosis in melanoma cells in vitro.³⁹ When combined with tamoxifen, it was more effective than either agent alone both in the A375 and G361 human melanoma cell lines.³⁹

Cannabinoids: Although endocannabinoid system apparently does not influence melanoma growth and progression, a study showed that cannabinoid type 1 receptor might serve as a tumor-promoting signal in human melanoma cells.¹⁸ Moreover, activation of cannabinoid receptors in melanoma cells showed a decrease in angiogenesis, proliferation, and metastasis, by altering Akt protein and pRb phosphorylation.¹⁷ Anandamide, 2-arachidonoylglycerol, and palmitoylethanolamide have proven anti-melanoma effects in murine models. Additionally, mice treated with Tetrahydrocannabinol have shown inhibition of tumor growth and decreased melanoma viability and proliferation.¹⁷

2. Herbal formulas:

“Black salve” (*Sanguinaria canadensis*) has shown to induce melanoma-cells death through caspase signaling pathway and oxidative stress. We found 2 cases of melanoma treated with topical “black salve” by patient’s initiative. In both cases, the site of the application presented ulceration and evolved with local recurrence and metastatic disease.²⁰ Furthermore, eschars formed by this formulation can mimic melanoma and obscure clinical evaluation.

3. Vitamin C:

At millimolar concentrations vitamin C reduced cell viability, invasiveness, and induced apoptosis in vitro. At micromolar concentrations promoted cell growth, migration, and cell cycle progression, and protected against mitochondrial stress, with higher tumor volume in mice compared to control group. Furthermore, vitamin C displayed synergistic cytotoxicity with Vemurafenib.⁴⁶

Discussion:

In this article, we have reviewed the published data on CAM on skin cancers. It is undeniable that many patients look for and use CAM therapies, so clinicians must be informed regarding the different compounds (Figure 1). The attitude and perception of CAM is improving among physicians, as shown in an Italian study where 42% believed that CAM could have an integrative role.⁴⁷ It is important to highlight that many ‘conventional’ dermatologic treatments widely used nowadays, have derived from ‘natural’ compounds (e.g., tacrolimus, 8-methoxysoralen, podophyllin, and salicylates, among others).¹ We

believe that a comprehensive knowledge of the role of CAM (Table 1) can strengthen the patient-physician relationship, potentially improving patient care.¹

There are several CAM therapies used on patients with skin cancer, and while most studies are in an experimental phase and have never been formally tested in humans, some have proven biological plausibility with potential clinical utility in the future. Clinicians should keep in mind that patient satisfaction from CAM ranges from 20% to 86% and *specifically* ask their patients about concurrent or past CAM use.⁴⁸ Asking patients regarding CAM use is important given there are inherent risks associated to CAM usage, including (1) avoidance and/or delay of assessment of conventional treatments, (2) potential side effects as a direct result of the CAM itself or from the (3) interaction with concurrent or future conventional therapies. For instance, turmeric has been found to decrease CYP450 activity and to inhibit cyclophosphamide-induced apoptosis and tumor regression. For specific side effects and interactions with specific agents see weblinks in Table 1. Of CAM users, 37% have found to be at risk of interaction with their conventional therapies; and for Chinese herbs, this can reach up to 88%.⁴⁹ This has special relevance when treating patients with comorbidities that use anticoagulants/antiplatelets or nonsteroidal anti-inflammatory drugs, where the risk of interaction is as high as 50%. Other drugs that may harm in combination with CAM are statins and hypoglycemic drugs.⁴⁹ Particular consequences should be considered when treating metastatic disease with systemic drugs, where the risk of interaction is even greater. In patients with systemic melanoma who receive systemic therapy (including interferon, chemotherapy, BRAF-inhibitors, and ipilimumab) and concurrent CAM use, the risk of interaction was as high as 85%.⁴⁹ Clinicians should also consider that CAMs have the potential of severe medical side effects (e.g. Ginkgo leaf extract has been linked to intracerebral hemorrhage) and not overlook these compounds. Furthermore, use of alternative therapies instead of conventional therapies was associated with worse survival rates for cancer patients.⁴⁷

Conclusion:

Even though there is growing evidence for a role of CAM in skin cancer, most therapies currently used by patients have no formal medical indications and bear possible severe complications. Physicians should educate themselves on CAMs to further educate their patients and lower the risk of interactions or the risk of omission of traditional, evidence-based therapies. We encourage clinicians to specifically ask patients for CAM use, to evaluate and avoid potential side effects. Despite emerging studies on animals, to date, there is no evidence from human clinical trials supporting the effectiveness of any CAM in the treatment of skin cancer, and future research must be done to elucidate their role in this field.

Founding source:

This research is funded in part by grant from the National Cancer Institute / National Institutes of Health (P30-CA008748) made to the Memorial Sloan Kettering Cancer Center.

Abbreviations used:

Bcl-2 B-cell lymphoma 2

ERK 1/2	Extracellular signal regulated kinase 1 and 2
SCC	squamous cell carcinoma
PCNA	Proliferating Cell Nuclear Antigen
MMP-2	matrixmetalloproteinase-2
MMP-9	matrixmetalloproteinase-9
ATM	Ataxia-telangiectasia-mutated
ATR	Ataxia telangiectasia and Rad3-related
BRCA1	breast cancer 1
Chk1	Checkpoint kinase 1
Chk2	Checkpoint kinase 2
TNFR	Tumor necrosis factor receptor
NF-κB	nuclear factor kappa-light-chain-enhancer of activated B cells
STAT3	<i>Signal transducer and activator of transcription 3</i>
mTOR	mammalian Target of Rapamycin
CB1	Cannabinoid receptor type 1
CB2	Cannabinoid receptor type 2
NMSC	Non-melanoma skin cancer
Bcl-XL	B-cell lymphoma-extra large
MAPK	Mitogen-activated protein kinase
TYR	Tyrosinase
TRP-1	Tyrosinase related protein 1
TRP-2	Tyrosinase related protein 2
mRNA	Messenger RNA
FasL	Fas ligand
IL-8	Interleukin 8
PKCα	Protein kinase C alpha
NO	Nitric oxide
IL-6	Interleukin 6
PI3K	phosphatidylinositide 3-kinases

MAPK	mitogen-activated protein kinase
JNK	c-Jun N-terminal kinases
MITF	Microphtalmia-associated transcription factor
CDK2	Cyclin- dependent kinase 2
CDK4	Cyclin- dependent kinase 4
TSP1	thrombospondin-1
AP-1	Activator protein 1
α-MSH	α-Melanocyte-stimulating hormone
ROS	reactive oxygen species
IL-1β	<i>Interleukin 1 beta</i>
iNOS	Inducible nitric oxide synthase
COX-2	Cyclooxygenase-2
MMPs	matrixmetalloproteinases
IL-12	<i>Interleukin 12</i>
TNFα	Tumor necrosis factor alpha
NLRP1	Nuclear localization leucine-rich-repeat protein 1
IL-2	Interleukin 2
IL-10	Interleukin 10
DNA-PKcs	DNA-dependent protein kinase catalytic subunit expression
PRL-3	Phosphatase of regenerating liver-3
MST1	Mammalian Sterile 20-like kinase 1
PDE	Cyclic nucleotide phosphodiesterases
STAT1	<i>Signal transducer and activator of transcription 1</i>
IFN-γ	Interferon gamma
MPTP	Mitochondrial permeability transition pore opening
HSP	Heat shock proteins
CB1	Cannabinoid receptor type 1
CB2	Cannabinoid receptor type 2
PEA	Palmitoylethanolamide

THC**Tetrahydrocannabinol****References:**

1. Pourang A, Hendricks AJ, Shi VY. Managing dermatology patients who prefer “all natural” treatments. *Clin Dermatol* 2020;38:348–53. [PubMed: 32563348]
2. Motoo Y, Yukawa K, Hisamura K, Tsutani K, Arai I. Internet survey on the provision of complementary and alternative medicine in Japanese private clinics: a cross-sectional study. *J Integr Med* 2019;17:8–13. [PubMed: 30482472]
3. Loquai C, Dechent D, Garzaroli M, et al. Use of complementary and alternative medicine: A multicenter cross-sectional study in 1089 melanoma patients. *Eur J Cancer* 2017;71:70–9. [PubMed: 27984769]
4. Dinehart SM, Alstadt K. Use of alternative therapies by patients undergoing surgery for nonmelanoma skin cancer. *Dermatol Surg* 2002;28:443–6. [PubMed: 12081668]
5. Söllner W, Zingg-Schir M, Rumpold G, Fritsch P. Attitude toward alternative therapy, compliance with standard treatment, and need for emotional support in patients with melanoma. *Arch Dermatol* 1997;133:316–21. [PubMed: 9080891]
6. Jellinek N, Maloney ME. Escharotic and other botanical agents for the treatment of skin cancer: a review. *J Am Acad Dermatol* 2005;53:487–95. [PubMed: 16112359]
7. Zhang YH, Peng HY, Xia GH, Wang MY, Han Y. Anticancer effect of two diterpenoid compounds isolated from *Annona glabra* Linn. *Acta Pharmacol Sin* 2004;25:937–42. [PubMed: 15210069]
8. Takasaki M, Konoshima T, Murata Y, et al. Anticarcinogenic activity of natural sweeteners, cucurbitane glycosides, from *Momordica grosvenori*. *Cancer Lett* 2003;198:37–42. [PubMed: 12893428]
9. Hostanska K, Daum G, Saller R. Cytostatic and apoptosis-inducing activity of boswellic acids toward malignant cell lines in vitro. *Anticancer Res* 2002;22:2853–62. [PubMed: 12530009]
10. Khuda-Bukhsh AR, Bhattacharyya SS, Paul S, Boujedaini N. Polymeric nanoparticle encapsulation of a naturally occurring plant scopoletin and its effects on human melanoma cell A375. *Zhong Xi Yi Jie He Xue Bao* 2010;8:853–62. [PubMed: 20836976]
11. Auriemma M, Di Nicola M, Gonzalez S, Piaseiro S, Capo A, Amerio P. Polypodium leucotomos supplementation in the treatment of scalp actinic keratoses: could it improve the efficacy of photodynamic therapy? *Dermatol Surg* 2015;41:898–902. [PubMed: 26218723]
12. Prasad RR, Paudel S, Raina K, Agarwal R. Silibinin and non-melanoma skin cancers. *J Tradit Complement Med* 2020;10:236–44. [PubMed: 32670818]
13. Zhao G, Han X, Cheng W, et al. Apigenin inhibits proliferation and invasion, and induces apoptosis and cell cycle arrest in human melanoma cells. *Oncol Rep* 2017;37:2277–85. [PubMed: 28260058]
14. Carletto B, Berton J, Ferreira TN, et al. Resveratrol-loaded nanocapsules inhibit murine melanoma tumor growth. *Colloids Surf B Biointerfaces* 2016;144:65–72. [PubMed: 27070053]
15. Almalki Z, Algregri M, Alhosin M, Alkhaled M, Damiati S, Zamzami MA. In vitro cytotoxicity of curcuminoids against head and neck cancer HNO97 cell line. *Braz J Biol* 2021;83:e248708. [PubMed: 34468533]
16. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. *Anticancer Res* 2001;21:2895–900. [PubMed: 11712783]
17. Ladin DA, Soliman E, Griffin L, Van Dross R. Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents. *Front Pharmacol* 2016;7:361. [PubMed: 27774065]
18. Carpi S, Fogli S, Polini B, et al. Tumor-promoting effects of cannabinoid receptor type 1 in human melanoma cells. *Toxicol In Vitro* 2017;40:272–9. [PubMed: 28131817]
19. Lim A Black salve treatment of skin cancer: a review. *J Dermatolog Treat* 2018;29:388–92. [PubMed: 29098921]

20. Leecy TN, Beer TW, Harvey NT, et al. Histopathological features associated with application of black salve to cutaneous lesions: a series of 16 cases and review of the literature. *Pathology* 2013;45:670–4. [PubMed: 24150196]
21. Lambert JD, Sang S, Dougherty A, et al. Cytotoxic lignans from *Larrea tridentata*. *Phytochemistry* 2005;66:811–5. [PubMed: 15797607]
22. Lo CY, Liu PL, Lin LC, et al. Antimelanoma and antityrosinase from *Alpinia galangal* constituents. *ScientificWorldJournal* 2013;2013:186505. [PubMed: 24027439]
23. Nakashima S, Oda Y, Nakamura S, et al. Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of *Lawsonia inermis* (Henna). *Bioorg Med Chem Lett* 2015;25:2702–6. [PubMed: 25987378]
24. Meng TX, Irino N, Kondo R. Melanin biosynthesis inhibitory activity of a compound isolated from young green barley (*Hordeum vulgare L.*) in B16 melanoma cells. *J Nat Med* 2015;69:427–31. [PubMed: 25827948]
25. Nakashima S, Matsuda H, Oda Y, Nakamura S, Xu F, Yoshikawa M. Melanogenesis inhibitors from the desert plant *Anastatica hierochuntica* in B16 melanoma cells. *Bioorg Med Chem* 2010;18:2337–45. [PubMed: 20189399]
26. Ghosh S, Bishayee K, Paul A, et al. Homeopathic mother tincture of *Phytolacca decandra* induces apoptosis in skin melanoma cells by activating caspase-mediated signaling via reactive oxygen species elevation. *J Integr Med* 2013;11:116–24. [PubMed: 23506692]
27. Chakraborty D, Ghosh S, Bishayee K, Mukherjee A, Sikdar S, Khuda-Bukhsh AR. Antihyperglycemic drug *Gymnema sylvestre* also shows anticancer potentials in human melanoma A375 cells via reactive oxygen species generation and mitochondria-dependent caspase pathway. *Integr Cancer Ther* 2013;12:433–41. [PubMed: 23615751]
28. Goldberg KH, Yin AC, Mupparapu A, Retzbach EP, Goldberg GS, Yang CF. Components in aqueous *Hibiscus rosa-sinensis* flower extract inhibit in vitro melanoma cell growth. *J Tradit Complement Med* 2017;7:45–9. [PubMed: 28053887]
29. Barbieri A, Quagliariello V, Del Vecchio V, et al. Anticancer and Anti-Inflammatory Properties of *Ganoderma lucidum* Extract Effects on Melanoma and Triple-Negative Breast Cancer Treatment. *Nutrients* 2017;9.
30. Valiahdi SM, Iranshahi M, Sahebkar A. Cytotoxic activities of phytochemicals from *Ferula* species. *Daru* 2013;21:39. [PubMed: 23701832]
31. Ling B, Michel D, Sakharlark MK, Yang J. Evaluating the cytotoxic effects of the water extracts of four anticancer herbs against human malignant melanoma cells. *Drug Des Devel Ther* 2016;10:3563–72.
32. Shin DH, Kim OH, Jun HS, Kang MK. Inhibitory effect of capsaicin on B16-F10 melanoma cell migration via the phosphatidylinositol 3-kinase/Akt/Rac1 signal pathway. *Exp Mol Med* 2008;40:486–94. [PubMed: 18985006]
33. Danciu C, Borcan F, Bojin F, Zupko I, Dehelean C. Effect of the isoflavone genistein on tumor size, metastasis potential and melanization in a B16 mouse model of murine melanoma. *Nat Prod Commun* 2013;8:343–6. [PubMed: 23678808]
34. Aronchik I, Kundu A, Quirit JG, Firestone GL. The antiproliferative response of indole-3-carbinol in human melanoma cells is triggered by an interaction with NEDD4-1 and disruption of wild-type PTEN degradation. *Mol Cancer Res* 2014;12:1621–34. [PubMed: 25009292]
35. Vaid M, Singh T, Prasad R, Katiyar SK. Bioactive proanthocyanidins inhibit growth and induce apoptosis in human melanoma cells by decreasing the accumulation of β -catenin. *Int J Oncol* 2016;48:624–34. [PubMed: 26676402]
36. Pal HC, Baxter RD, Hunt KM, et al. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. *Oncotarget* 2015;6:28296–311. [PubMed: 26299806]
37. Kwak JY, Seok JK, Suh HJ, et al. Antimelanogenic effects of luteolin 7-sulfate isolated from *Phyllospadix iwatensis* Makino. *Br J Dermatol* 2016;175:501–11. [PubMed: 26914711]
38. Ju EM, Lee SE, Hwang HJ, Kim JH. Antioxidant and anticancer activity of extract from *Betula platyphylla* var. *japonica*. *Life Sci* 2004;74:1013–26. [PubMed: 14672757]

39. Sood S, Jayachandiran R, Pandey S. Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma. *Integr Cancer Ther* 2021;20:1534735421990078.
40. Alipanah H, Farjam M, Zarenezhad E, Roozitalab G, Osanloo M. Chitosan nanoparticles containing limonene and limonene-rich essential oils: potential phytotherapy agents for the treatment of melanoma and breast cancers. *BMC Complement Med Ther* 2021;21:186. [PubMed: 34215240]
41. Zhang J, Lei Z, Huang Z, et al. Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity. *Oncotarget* 2016;7:79557–71. [PubMed: 27791197]
42. Mirzaei H, Naseri G, Rezaee R, et al. Curcumin: A new candidate for melanoma therapy? *Int J Cancer* 2016;139:1683–95. [PubMed: 27280688]
43. Zhao G, Han X, Zheng S, et al. Curcumin induces autophagy, inhibits proliferation and invasion by downregulating AKT/mTOR signaling pathway in human melanoma cells. *Oncol Rep* 2016;35:1065–74. [PubMed: 26573768]
44. Zhang YP, Li YQ, Lv YT, Wang JM. Effect of curcumin on the proliferation, apoptosis, migration, and invasion of human melanoma A375 cells. *Genet Mol Res* 2015;14:1056–67. [PubMed: 25730045]
45. Zheng M, Ekmekcioglu S, Walch ET, Tang CH, Grimm EA. Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. *Melanoma Res* 2004;14:165–71. [PubMed: 15179184]
46. Yang G, Yan Y, Ma Y, Yang Y. Vitamin C at high concentrations induces cytotoxicity in malignant melanoma but promotes tumor growth at low concentrations. *Mol Carcinog* 2017;56:1965–76. [PubMed: 28370562]
47. Berretta M, Rinaldi L, Taibi R, et al. Physician Attitudes and Perceptions of Complementary and Alternative Medicine (CAM): A Multicentre Italian Study. *Front Oncol* 2020;10:594. [PubMed: 32411599]
48. Vapiwala N, Mick R, Hampshire MK, Metz JM, DeNittis AS. Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis. *Cancer J* 2006;12:467–74. [PubMed: 17207316]
49. Loquai C, Schmidtmann I, Garzarolli M, et al. Interactions from complementary and alternative medicine in patients with melanoma. *Melanoma Res* 2017;27:238–42. [PubMed: 28252553]
50. Lopez G, Mao JJ, Cohen L. Integrative Oncology. *Med Clin North Am* 2017;101:977–85. [PubMed: 28802474]





Figure 1:

Examples of herbs with compounds studied on skin cancer.

Figure 1A: celery (red arrow), grape seeds (green arrow), ground turmeric (curcuma, on orange arrow), and parsley (blue arrow). Photographs by Karina Carrasco and Leonel Hidalgo.

**Figure 1B:**

1. Ginger; 2. Olives; 3. Parsley; 4. Eucalyptus; 5. Thyme; 6. Mangoes; 7. Apple; 8. Blueberries (one of the many kinds of berries); 9. Kiwis; 10. Cucumbers; 11. Carrots; 12. Broccoli; 13. Chili peppers; 14. Pepper; 15. Peanuts; 16. Cauliflower; 17. Celery; 18. Green tea; 19. Strawberries; 20. Soybeans; 21. Rosemary; 22. Artichokes. Photographs by Karina Carrasco and Leonel Hidalgo.

Table 1:

Recommended Internet resources for integrative oncology. Modified from Lopez, et al.⁵⁰

Memorial Sloan Kettering Cancer Center	https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine
University of Texas MD Anderson Center, Integrative Medicine Program	https://www.mdanderson.org/patients-family/diagnosis-treatment/care-centers-clinics/integrative-medicine-center.html
Natural Medicines Comprehensive Database	https://naturalmedicines.therapeuticresearch.com
National Center for Complementary and Integrative Health	www.nccih.nih.gov
National Cancer Institute: Office of Cancer Complementary and Alternative Medicine	https://cam.cancer.gov
American Institute for Cancer Research	www.aicr.org
Society for Integrative Oncology	www.integrativeonc.org

Table 2:

Summary of complementary and alternative therapies evaluated for non-melanoma skin cancer with most available evidence.

Agent	Mechanism of action	Effect in vitro / animal models	Effect in human participants	Potential for harm/toxicity	Level of evidence*
Botanical agents					
Goldenseal (<i>Hydrastis canadensis</i>)	<ul style="list-style-type: none"> Inhibits glucose uptake inhibiting skin carcinogenesis 	In vitro / Mice	No	<ul style="list-style-type: none"> Potentially hinder glucose control in people with type 2 diabetes taking metformin (reduces 25% level) May be safe taken alone, but there are not reliable studies that evaluate its safety. 	5
Pond apple (<i>Annona glabra</i>)	<ul style="list-style-type: none"> Down-regulates Bcl-2 gene Up-regulates Bax gene Antiproliferative effect 	In vitro	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
Bitter melon (<i>Momordica charantia</i>)	<ul style="list-style-type: none"> Molecular pathway not available Inhibits carcinogenesis 	Mice	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
Ginger (<i>Zingiber officinale</i>)	<ul style="list-style-type: none"> Molecular pathway not available Inhibits skin tumor initiation and promotion 	Mice	No	<ul style="list-style-type: none"> Used safely on dietary supplement and topical use. Abdominal discomfort, heartburn, diarrhea, and mouth and throat irritation, especially if taken in large doses. 	5
Willow tree bark (<i>Salix caprea</i>)	<ul style="list-style-type: none"> Inhibits oxidative stress and ornithine decarboxylase activity with anti-carcinogenesis effects 	Mice	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
Frankincense (<i>Boswellia serrata</i>)	<ul style="list-style-type: none"> Activates caspase-8 pathway and inhibits phosphorylation of the ERK 1/2 with antiproliferative effect 	In vitro / Mice	Case reports	<ul style="list-style-type: none"> When added in escharotic agents: subclinical extension of tumor. Scarring and tissue damage, which could lead to disfiguring. 	5
Sodom apple plant (<i>Solanum sodomaeum</i>)	<ul style="list-style-type: none"> Not available. 	In vitro / Mice	Case reports: cream formulation has shown efficacy on BCC, SCC, keratoacanthomas, and actinic keratosis at least 3 years after cessation of therapy	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
Plants of the genus <i>Gelsemium</i>	<ul style="list-style-type: none"> Increases production of PCNA with antiproliferative and proapoptotic effect 	In vitro / Mice	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
<i>Polypodium leucotomos</i>	<ul style="list-style-type: none"> Decreases cyclobutane pyrimidine dimers Decreases epidermal cells and dermal mast cell infiltration Photoprotective effects against UVR. 	In vitro / Mice	Case reports: Increases the efficacy of photodynamic therapy in actinic keratosis	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
Phytochemicals					

Agent	Mechanism of action	Effect in vitro / animal models	Effect in human participants	Potential for harm/toxicity	Level of evidence *
Resveratrol	<ul style="list-style-type: none"> Inhibits MMP-2 and MMP-9 secretion with antiproliferative effects on SCC models 	In vitro	No	<ul style="list-style-type: none"> May increase concentrations of pimozide (by CYP3A4 inhibition) 	5
Cryptolepine	<ul style="list-style-type: none"> Increases phosphorylation of ATM/ATR, BRCA1, Chk1/Chk2 and γH2AX. Activates of p53 signaling pathway Downregulates cyclin-dependent kinases, cyclin D1, cyclin A, cyclin E and proteins involved in cell division Antiproliferative and proapoptotic effects 	In vitro	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
Apigenin	<ul style="list-style-type: none"> Proapoptotic effect through TNFR- and Bcl-2-mediated pathway 	In vitro: Enhances susceptibility of head and neck SCC to 5-fluorouracil and cisplatin	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
Curcumin	<ul style="list-style-type: none"> Inhibits NF-κB signaling pathway, Akt, ERK1/2, STAT3 with antiproliferative and proapoptotic effects Up-regulates miR-9 expression Suppresses Wnt/β-catenin signaling pathway Decreases cyclin D1 level Inhibits mTOR signaling pathway Antiproliferative effects on oral SCC 	In vitro / Mice	<ul style="list-style-type: none"> Case reports and case series: chemoprevention of cancer, including arsenic Bowen's disease and oral leukoplakia 	<ul style="list-style-type: none"> No treatment-related toxicity up to 8,000 mg/day 	4
Curcuminooids	<ul style="list-style-type: none"> Inhibites proliferation of HNO97 cell lines (Human oral squamous cell carcinoma). Morphological changes of HNO97 cell lines: appearance of apoptosis. Induces apoptosis of HNO97 cell lines in a time-dependent manner. Alters the cell cycle distribution of HNO97 cell lines DNA damage in HNO97 cell lines. Suppresses the colony-forming ability of HNO97 cell lines in a time-dependent manner. 	In vitro	<ul style="list-style-type: none"> Case reports 	<ul style="list-style-type: none"> Safely when taken orally or applied to the skin (turmeric) but lacks bioavailability. 	5
Silymarin/Silibinin	<ul style="list-style-type: none"> Protects against UVB-induced thymine dimer formation. Promotes DNA repair. Apoptosis in damaged cells via an increase in p53 levels. Target aberrant signaling pathways Induction of anti-inflammatory responses (TNFα, IL-1α and COX-2 pathway). 	In vitro	No	<ul style="list-style-type: none"> Milk thistle (contains silymarin) may lower blood sugar levels in people with type 2 diabetes 	5
<i>Herbal formulas</i>					
“Black salve”	<ul style="list-style-type: none"> Inhibits NF-κB with proapoptotic effect 	In vitro	<ul style="list-style-type: none"> Case reports: complete BCC remission cases and residual infiltrating BCC. 	<ul style="list-style-type: none"> When added in escharotic agents: subclinical extension of tumor Scarring and tissue damage, which could lead to disfiguring. 	5
<i>Cannabinoids</i>					
Exogenous cannabinoids	<ul style="list-style-type: none"> CB1 and CB2 activation shows antitumor effect in skin papillomas and NMSC in mice 	In vitro / Mice	No	<ul style="list-style-type: none"> Cannabis: risk of motor vehicle crashes, lower birth weight when consumed on 	5

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Agent	Mechanism of action	Effect in vitro / animal models	Effect in human participants	Potential for harm/toxicity	Level of evidence*
	• Prevented growth and vascularization of malignant epidermal tumor cells			pregnancy, orthostatic hypotension, severe mental illnesses (in predisposed).	
Anandamide	• Elevated in skin tumor cells, leading to cell apoptosis	In vitro	No	• Not reliable studies that evaluate its safety.	5

* Level of evidence based on www.ebmconsult.com/articles/levels-of-evidence-and-recommendations

Table 3:

Summary of complementary and alternative therapies evaluated for melanoma skin cancer with most available evidence.

Agent	Mechanism of action	Effect in vitro / animal models	Effect in human participants	Potential for harm/toxicity	Level of evidence*
Botanical agents					
Tea tree oil (<i>Melaleuca alternifolia</i>)	• Activates caspase-dependent apoptosis	In vitro	No	• Not reliable studies that evaluate its safety.	5
Slippery elm (<i>Ulmus rubra</i>)	• Oligonucleosomal fragmentation • Activates caspase-3 signaling pathway • Decreases expression of Bcl-2 gene and Bcl-XL gene • Increases expression of Bax gene • Propapoptotic effect	In vitro	No	• Not reliable studies that evaluate its safety.	5
Chapparel (<i>Larrea tridentata</i>)	• Molecular pathway not described • Tumor growth inhibition	In vitro	No	• Not reliable studies that evaluate its safety.	5
<i>Alpinia galanga</i>	• Inhibits MAPK signaling pathway • Inhibits p44/42 signaling pathway • Inhibits NF- κ B signaling pathway • Antiproliferative and cytotoxic effects	In vitro	No	• Not reliable studies that evaluate its safety.	5
Flower buds of <i>Lawsonia inermis</i> (Henna)	• Inhibits TYR, TRP-1 and TRP-2 and mRNA expression • Antimelanogenesis effect	In vitro	No	• Not reliable studies that evaluate its safety.	5
Young green barley (<i>Hordeum vulgare L.</i>)	• Molecular pathway not described • Inhibits activity in melanoma cells	In vitro	No	• Not reliable studies that evaluate its safety.	5
The desert plant <i>Anastatica hierochuntica</i>	• Inhibits phosphorylation of ERK1/2 • mRNA expression of tyrosinase and TRP-1 and -2 is contradictory • Inhibits melanogenesis	In vitro	No	• Not reliable studies that evaluate its safety.	5
Homeopathic mother tincture (<i>Phytolacca decandra</i>)	• Generates oxidative damage • Down-regulates of Akt and Bcl-2 gene • Up-regulates of Bax gene, p53, and caspase 3 signaling pathway • Antiproliferative and proapoptotic effects	In vitro	No	• Not reliable studies that evaluate its safety.	5
Gurmar or woody climber tree (<i>Gymnema sylvestre</i>)	• Causes DNA fragmentation • Increases level of mRNA expression of apoptotic signal related genes	In vitro	No	• Not reliable studies that evaluate its safety.	5
Hibiscus rosa-sinensis flower extract	• Induces caspases cleavages, Bcl-2 family proteins regulation, and Fas/FasL activation • Antiproliferative effects and induces autophagy	In vitro	No	• Not reliable studies that evaluate its safety.	5
Lingzhi (<i>Ganoderma lucidum</i>)	• Inhibits release of IL-8, IL-6, MMP-2, and MMP-9 • Decreases viability of melanoma cells	In vitro	No	• Not reliable studies that evaluate its safety.	5
Yellow jessamine (<i>Gelsemium sempervirens</i>)	• Down-regulates cyclin-D1, PCNA, survivin, and STAT-3 • Up-regulates of p53 and caspase-3 signaling pathway • Proapoptotic effect	In vitro	No	• Not reliable studies that evaluate its safety.	5

Agent	Mechanism of action	Effect in vitro / animal models	Effect in human participants	Potential for harm/toxicity	Level of evidence *
<i>Solanum nigrum</i>	<ul style="list-style-type: none"> Decreases MMP-9, Akt activity and PKCα, Ras, and NF-κB protein expressions Cytostatic and cytotoxic effect against human and mouse melanoma cells 	In Vitro / Mice	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
<i>Hedysarum diffusum</i>	<ul style="list-style-type: none"> Activates caspase-3, caspase-8, and caspase-9 Antiproliferative effect 	In vitro	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
<i>Panax ginseng</i>	<ul style="list-style-type: none"> Increases the production of TNF-alpha, NO and IL-6. Regulates the C-jun N-terminal kinase phosphorylation, and p38. Activates Akt, MAPKs, and NF-κB Induces cell death in vitro Reduces melanoma cell viability 	In vitro	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
Phytochemicals					
Capsaicin	<ul style="list-style-type: none"> Depletion of substance P Inhibits PI3K, Akt, mTOR and NF-κB Antiangiogenesis, and proapoptotic effects 	In vitro	No	<ul style="list-style-type: none"> Topical: Application site burning, erythema, pain, pruritis, edema, blister, scar. 	5
Genistein	<ul style="list-style-type: none"> Inhibits Akt, MAPK, P38 and JNK signaling pathway Anti-angiogenesis, antiproliferative and proapoptotic effects 	In vitro	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
Indole-3-carbinol	<ul style="list-style-type: none"> Inhibits Akt and MITF with antiproliferative and proapoptotic effects 	In vitro	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
Proanthocyanidins	<ul style="list-style-type: none"> Inhibits NF-κB and ERK1/2 with antiproliferative effect 	In vitro	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
Resveratrol	<ul style="list-style-type: none"> Increases Connexin 43 gap junction communications Decreases expression of cyclin B, cyclin D, CDK-2 and CDK-4 Decreases expression FLIP gene, Bcl-2, and survivin Inhibits ERK1/2 Increases tumor suppressor protein 53 and matrix protein TSP1 Antiproliferative effects 	In vitro	No	<ul style="list-style-type: none"> May increase concentrations of pinozide (by CYP3A4 inhibition) 	5
Apigenin	<ul style="list-style-type: none"> increases ROS Activates caspase-3 signaling pathway Decreases phosphorylation of ERK1/2 proteins, Akt and mTOR Antiproliferative and proapoptotic effects 	In vitro	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
Quercetin	<ul style="list-style-type: none"> Up-regulates CDK inhibitors p27(KIP1) and p21(CIP1) Antioxidant, cell cycle arrest and proapoptotic activity 	In vitro	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
Silymarin and silybin	<ul style="list-style-type: none"> Decreases phosphorylation of ERK1/2 and RSK2, Decreases activation of NF-κB, AP-1, and STAT3 Increases casein kinase 1α and glycogen synthase kinase-3β Decreases nuclear β-catenin Inhibits of MMP-2 and MMP-9 Antiproliferative, cell cycle arrest and proapoptotic effect 	In vitro	No	<ul style="list-style-type: none"> Milk thistle (contains silymarin) may lower blood sugar levels in people with type 2 diabetes 	5
Epigallocatechin-3-gallate	<ul style="list-style-type: none"> Inhibits cell growth, EMT and invasion Inhibits NF-κB signaling pathway 	In vitro	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5

Agent	Mechanism of action	Effect in vitro / animal models	Effect in human participants	Potential for harm/toxicity	Level of evidence *
Chrysin	<ul style="list-style-type: none"> Decreases IL-1β secretion, inhibited iNOS, COX-2, MMPs, IL-6, IL-8, IL-12 and TNFα. Down-regulates the inflammasome Decreases NLRP1 Reduces caspase-1 activation Induces cell cycle arrest and apoptosis 				
Paradise tree extract	<ul style="list-style-type: none"> Stimulates IL-2, IL-10 expression in mice melanoma cells Apoptosis in melanoma cells from the A375 and G361 cell lines in-vitro 	In vitro	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
Berberine	<ul style="list-style-type: none"> Increases melanoma cell levels of ROS and produces AMPK activation Downregulation of ERK and p38 MAPK Reduction in COX-2, PGE2 and PGF2 receptors 	In vitro / Mice	No	<ul style="list-style-type: none"> Golden seal (contains berberine); potentially hinder glucose control in people with type 2 diabetes taking metformin reduces 25% level) May be safe taken alone, but there are not reliable studies that evaluate its safety. 	5
Pancratistatin	<ul style="list-style-type: none"> Targets mitochondrial vulnerabilities Apoptosis in melanoma cells (A375) In combination with tamoxifen is more effective than either agent standalone (in-vitro) 	In vitro	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
Cureumin	<ul style="list-style-type: none"> Anti-inflammatory and anti-oxidative pathways which allow it to selectively target melanoma cells. Up-regulates of miRNA, p53, p21(Cip1), p27(Kip1) and checkpoint kinase 2 Down-regulates of anti-apoptotic Bcl-2, PCNA, iNOS, DNA-PKcs expression, PRL-3, anti-apoptotic McI-1 protein Activates caspase-3, caspase 8, MST1 gene Inhibits of NF-κB, PDE 1 to 5 Inhibits phosphorylation of STAT1 and STAT3, MMP-2, mTOR activity Increases levels of IFN-γ secretion and production of granzyme b or IFN-γ. Reduces level of IL-12. Akt phosphorylation has shown contradictory results. Induces MPTP opening Multiple antioxidant, antiproliferative, proapoptotic effects on melanoma cells in vitro and murine models. Poor bioavailability when tested in-vivo mouse models. 	In vitro / Mice	No	<ul style="list-style-type: none"> Safely when taken orally but lacks bioavailability. 	5
<i>Curcuminoïds</i>					
EF24	<ul style="list-style-type: none"> Inhibits the NF-κB 	In vitro	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5
DM-1	<ul style="list-style-type: none"> Modulates iNOS and COX-2 gene expression 	In vitro	No	<ul style="list-style-type: none"> Not reliable studies that evaluate its safety. 	5

Agent	Mechanism of action	Effect in vitro / animal models	Effect in human participants	Potential for harm/toxicity	Level of evidence *
D6	• Induces overexpression of HSP and induces melanoma cells apoptosis	In vitro	No	• Not reliable studies that evaluate its safety.	5
<i>Herbal formulas</i>					
"Black salve"	• Induces caspase signaling pathway and oxidative stress.	In vitro	Case reports: escharotic effect.	• When added in escharotic agents: subclinical extension of tumor • Scarring and tissue damage, which could lead to disfiguring. • In melanoma has been associated with ulcer, local recurrence, and metastatic disease	5
<i>Cannabinoids</i>					
CB1	• Tumor-promoting signal in human cutaneous melanoma	In vitro	No	• Not reliable studies that evaluate its safety.	5
CB1 and CB2	• Alters Akt protein and pRb phosphorylation decreasing angiogenesis, proliferation, and metastasis of melanoma	In vitro	No	• Not reliable studies that evaluate its safety.	5
PEA	• PEA in combination with URB597 (inhibitor of fatty acid amide hydrolase) decreases melanoma progression associated with increased PEA levels	In vitro	No	• Not reliable studies that evaluate its safety.	5
THC	• Inhibits tumor growth of transplanted melanoma, inhibiting tumor growth in mice	In vitro	No	• Cannabis: risk of motor vehicle crashes, lower birth weight when consumed on pregnancy, orthostatic hypotension, severe mental illnesses (in predisposed).	5
<i>Vitamin C</i>					
Vitamin C	• Decreases the phosphorylated form of BRAF gene (dose dependent) • Increases the phosphorylation of ERK • Increased the phosphorylated form of AKT which mediates cell survival and growth.	In vitro	No	• Oral: hyperoxaluria (with large doses), hemolysis (in patients with glucose-6-phosphate dehydrogenase deficiency).	5

* Level of evidence based on www.ebmconsult.com/articles/levels-of-evidence-and-recommendations